BioClinica, a provider of outsourced clinical trial services and eClinical Solutions, has announced that its Compass technology, a risk-based monitoring solution that improves overall quality in clinical trials, has won the inaugural Society for Clinical Data Management (SCDM) NextGen Technology Innovation (TIA) Award, presented as part of SCDM's 2014 annual conference.

BioClinica's entry utilizes "Intelligent Monitoring" to transform the way clinical trials are managed. Compass focuses on meaningful data, critical to the success of a trial, and makes it easy to view the overall performance of trial sites. Compass leverages intelligent monitoring to track trial performance and identify performance issues across sites and ensure the most efficient and effective use of resources.

The SCDM Award recognizes breakthrough innovations which use novel technologies or processes and provide real-life application for use in clinical trials. Compass, along with entrees from Maxisit and PHT, was chosen as a finalist from a broad field of entries.

Derek Perrin, SCDM vice-chair, said, "Compass is exactly the kind of technology solution we want to highlight with this award. It is an innovative solution to meeting the newest challenge in clinical trials."

"This award not only recognizes the value Compass brings to clinical research, it also represents the clinical trial community's interest and willingness to embrace a new approach to monitoring," said Mark Weinstein, BioClinica CEO. "The FDA has made it clear—we should be focusing our attention on the data that matters most—and Compass is a valuable tool to help trial sponsors accomplish this objective."